227 related articles for article (PubMed ID: 23898609)
21. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
23. [Progress of clinical pathology and application of PET-CT on thyroid carcinoma].
Gao M; Li XL; Yu Y; Sun BC; Li SL; Xu WG
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Jun; 41(6):419-24. PubMed ID: 16927796
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
[TBL] [Abstract][Full Text] [Related]
25. RANKL, OPG, TRAIL, KRas, and c-Fos expression in relation to central lymph node metastases in papillary thyroid carcinoma.
Deligiorgi MV; Mahaira H; Eftychiadis C; Kafiri G; Georgiou G; Theodoropoulos G; Konstadoulakis MM; Zografos E; Zografos GC
J BUON; 2018; 23(4):1029-1040. PubMed ID: 30358208
[TBL] [Abstract][Full Text] [Related]
26. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients.
Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E
Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188
[TBL] [Abstract][Full Text] [Related]
27. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
28. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.
Shi X; Liu R; Basolo F; Giannini R; Shen X; Teng D; Guan H; Shan Z; Teng W; Musholt TJ; Al-Kuraya K; Fugazzola L; Colombo C; Kebebew E; Jarzab B; Czarniecka A; Bendlova B; Sykorova V; Sobrinho-Simões M; Soares P; Shong YK; Kim TY; Cheng S; Asa SL; Viola D; Elisei R; Yip L; Mian C; Vianello F; Wang Y; Zhao S; Oler G; Cerutti JM; Puxeddu E; Qu S; Wei Q; Xu H; O'Neill CJ; Sywak MS; Clifton-Bligh R; Lam AK; Riesco-Eizaguirre G; Santisteban P; Yu H; Tallini G; Holt EH; Vasko V; Xing M
J Clin Endocrinol Metab; 2016 Jan; 101(1):264-74. PubMed ID: 26529630
[TBL] [Abstract][Full Text] [Related]
29. [Expression of Piwil2 and its relationship with tumor invasion and metastasis in papillary thyroid carcinoma].
Yin DT; Li HQ; Wang YF; Cao SL; Zhou YB; Zheng LY; Jiang JH; Wang QD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Mar; 46(3):237-9. PubMed ID: 21575418
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between methylation status of promoter and expression of XAF1 gene in papillary thyroid carcinoma].
Yin DT; Chen G; Li HQ; Zheng XY; Wang YF; Zhang Y; Jiang JH; Wang QD
Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(28):1967-70. PubMed ID: 22944270
[TBL] [Abstract][Full Text] [Related]
31. [Clinical analysis of lymphocytic thyroiditis coexistent with papillary thyroid carcinoma].
Wang SX; She ZQ; An CM; Zhang XW; Li ZJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 51(4):277-81. PubMed ID: 27095720
[TBL] [Abstract][Full Text] [Related]
32. Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.
Feng J; Shen F; Cai W; Gan X; Deng X; Xu B
Endocrine; 2018 Sep; 61(3):499-505. PubMed ID: 29909599
[TBL] [Abstract][Full Text] [Related]
33. [High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma].
Yue C; Zhao X; Tian C; Jin Y; Liu H
Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):490-4. PubMed ID: 26705040
[TBL] [Abstract][Full Text] [Related]
34. Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).
Rivera M; Tuttle RM; Patel S; Shaha A; Shah JP; Ghossein RA
Thyroid; 2009 Feb; 19(2):119-27. PubMed ID: 19191744
[TBL] [Abstract][Full Text] [Related]
35. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease.
Boutzios G; Vasileiadis I; Zapanti E; Charitoudis G; Karakostas E; Ieromonachou P; Karatzas T
Thyroid; 2014 Feb; 24(2):347-54. PubMed ID: 23786233
[TBL] [Abstract][Full Text] [Related]
36. Transforming Growth Factor β1 Could Influence Thyroid Nodule Elasticity and Also Improve Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Li Y; Wang Y; Wu Q; Hu B
Ultrasound Med Biol; 2015 Nov; 41(11):2866-72. PubMed ID: 26306431
[TBL] [Abstract][Full Text] [Related]
37. [Role of level VI lymph nodes metastasis in cervical metastasis of patients with papillary thyroid cancer].
Bian X; Chen H; Ye X; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 45(8):664-8. PubMed ID: 21055244
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of LC3 in Papillary Thyroid Carcinomas and Lymph Node Metastases.
Li X; Lin X; Ma H
Acta Chir Belg; 2015; 115(5):356-63. PubMed ID: 26560002
[TBL] [Abstract][Full Text] [Related]
39. The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.
Regalbuto C; Malandrino P; Frasca F; Pellegriti G; Le Moli R; Vigneri R; Pezzino V
J Endocrinol Invest; 2013 Apr; 36(4):249-54. PubMed ID: 22776915
[TBL] [Abstract][Full Text] [Related]
40. Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma.
Hu YJ; Luo XY; Yang Y; Chen CY; Zhang ZY; Guo X
Genet Mol Res; 2015 Nov; 14(4):15325-30. PubMed ID: 26634497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
